Neeraj Agarwal,
MD
Languages Spoken: English
Neeraj Agarwal, MD, is an Associate Professor in the Division of Oncology, Department of Medicine, at the University of Utah School of Medicine. He is the Director of the Genitourinary Oncology Program in the Oncology Division, the Co-leader of the Urologic Oncology Multidisciplinary Program and the Associate Director of Clinical Trials (solid tumors) at the Huntsman Cancer Institute (HCI).
As a specialist in adult hematology and oncology, Dr. Agarwal cares for patients with all types of cancer and specializes in genitourinary malignancies (cancers of the prostate, kidney, bladder and testes).
Dr. Agarwal is a member of several professional societies, including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR) and the Southwest Oncology Group (SWOG). After receiving his MD degree from All India Institute of Medical Sciences in New Delhi, India, Dr. Agarwal completed a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa. He then completed a hematology-oncology fellowship at HCI and the University of Utah School of Medicine.
Dr. Agarwal has received several awards and grants and has authored more than 150 peer-reviewed articles and book chapters. He has given talks at several prestigious regional and national forums, including the workshop at the National Institute of Health’s National Institute on Aging, Utah Urologic Society Annual meeting, and MD Anderson Cancer Center’s–sponsored oncology conferences. He serves as a panel member for the National Comprehensive Cancer Network (NCCN) guideline- committees for bladder, kidney cancer and testicular cancer. Dr. Agarwal also serves as the national principle investigator and chair of a National Cancer Institute (NCI) funded multicenter phase III clinical trial for men with newly diagnosed metastatic prostate cancer. This trial is sponsored by SWOG, one of the largest National Cancer Institute’s (NCI) clinical trials group, and endorsed by all major groups in NCI Clinical Trials Network ( ECOG, CALGB etc.). This trial is expected to recruit more than 1500 men with newly diagnosed metastatic prostate cancer across the United States. In addition, he is the Principal Investigator (PI) for three investigator-initiated clinical trials for men with prostate cancer, along with being a site PI for multiple other industry and cooperative group trials.
Dr. Agarwal has the prestigious honor of being chosen as one of the five young investigators of the Southwest Oncology Group in 2009. He has been appointed as the leader of early therapeutics of the SWOG Genitourinary Cancer Committee in 2010. Dr. Agarwal is also the recipient of the prestigious 2009-2010 William D. Odell Young Investigator award from the University of Utah’s, Department of Medicine, and the 2014 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.
Clinical Locations
Huntsman Cancer Hospital
Clinic 2B, GU801-585-0250
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Medical Oncology) American Board of Internal Medicine (Sub: Geriatric Medicine) |
| Cancer Center Programs | Experimental Therapeutics |
Patient Ratings
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survery.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.8/ 5
Care provider spoke using clear language
4.7/ 5
Care provider's explanation of condition/problem
4.7/ 5
My confidence in care provider
4.8/ 5
Care provider's effort to include me in decisions
4.7/ 5
Wait time at clinic
4.3/ 5
Time care provider spent with me
4.6/ 5
Care provider's concern for questions & worries
4.7/ 5
Care provider's friendliness and courtesy
4.8/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
April 28, 2017
A lot of information. Good experience but lots of things going on.
UofU Patient
March 19, 2017
I have the highest confidence in Dr. Agarwal and his staff.
UofU Patient
March 14, 2017
Julia Outstanding !
UofU Patient
March 05, 2017
we wouldn't want anyone else treating _____. Dr. Agarwal is the best!
UofU Patient
February 25, 2017
great personnel
UofU Patient
February 13, 2017
I'm very confident in his watchful care. I know he is making the right decisions for my health. It's always a pleasure to meet with him. I'm grateful that I have Dr. Agarwal for my provider as well as his Staff.
UofU Patient
February 04, 2017
Excellent meeting with the NP!
UofU Patient
January 13, 2017
thankful for the abilities of the Doctors
UofU Patient
December 14, 2016
highly encouraging, willing to cover questions thoroughly, easy to talk with.
UofU Patient
December 12, 2016
We feel very confident with Dr Agarwal.
UofU Patient
October 27, 2016
The Doctor is all ways friendly and helpful with my concerns.
UofU Patient
September 12, 2016
All good.
UofU Patient
September 07, 2016
I always recommend the hospital when I hear of problems involving cancer
UofU Patient
September 04, 2016
all good
UofU Patient
September 01, 2016
In the six years I have been coming here for care Dr. Agarwal and his staff have been the best! I am confident in all they do, I know they sincerely care about me and my cancer and are doing their very best. I know I wouldn't be here without them.
UofU Patient
August 29, 2016
great experience
UofU Patient
August 28, 2016
Doctor Agerwal seemed like he is only interested in himself. It was hard to listen to him because he was yelling. At first I thought he was going to be a good teacher, using the white board, but as time went on I realized he was not interested in answering any of my questions. In fact, it seemed like he was annoyed that I had the nerve to ask any questions. If I asked for him to clarify what he said, he seemed irritated. I have a Master's degree and am no dummy, but am interested in my condition and treatment. He seemed to treat me like I was an imbicile in the way he responded. It seemed like Dr. Agerwal was only interested in getting another body into his trial. He did not indicate from anything he said that he had read any information from my chart. There was no mention of any treatment I had had previously. Dr. Agerwal did not answer any questions about treatment side affects, but said that the pharmacist would do that(the pharmacist never spoke to us or came in). I have 0 confidence in this Doctor. After Dr. Agerwal left, I was told that I did not qualify for the treatment he had just spent an hour and a half yelling about. Why did he waste my time and his telling me about a treatment for which I did not qualify? I will do all I can to avoid going to him again. He did tell me about how much he has been published, and about how much he has done in drug trials and so forth. His "bedside manner " is non existant. The Fellow, Doctor Poole on the other han
UofU Patient
August 26, 2016
provided complete update as to husbands progress and gave us clear direction to follow going forward
UofU Patient
August 25, 2016
Huntsman is the best, they take care of my husband, and family also.
UofU Patient
August 23, 2016
I am starting radiation therapy next month. Huntsman is the only place I will go for treatment!
UofU Patient
August 15, 2016
they all are great clinicians
UofU Patient
August 13, 2016
great care
UofU Patient
August 13, 2016
I think Dr. Agerwal and his PSs are great and tell them so at each appointment.
UofU Patient
June 27, 2016
The degree we have confidence is much higher than 5.
UofU Patient
June 06, 2016
Julia is always great and very informative and concerned when their are questions.
UofU Patient
May 31, 2016
We always receive very personalized care with our providers in this clinic. We appreciate all of them and their skill, concern and effectiveness in helping us each time.
UofU Patient
April 26, 2016
I always receive great service when I go to the Huntsman Cancer Center.
UofU Patient
April 23, 2016
good
UofU Patient
April 19, 2016
Both the PA and Dr. Agarwal were excellent. In fact, the PA was exceptional.
UofU Patient
April 18, 2016
I left feeling that I was in very good hands
UofU Patient
April 18, 2016
The care level is over the top.
UofU Patient
April 04, 2016
My last scans/labs showed a changed in my condition. I feel that he was not ready to discuss it with me. In fact i had to bring it up. During what little conversation we had he got a text and answered it. It felt like he wanted to be somewhere else. I have all the confidence in the world in his abilities, but not a good visit.
UofU Patient
March 31, 2016
Great exp.
UofU Patient
March 09, 2016
He was in a hurry and had other patients to attend to. Seemed upset that I wanted more information. Finally left the room and returned after about 20 or 30 minutes. His English is not easily understood. After he returned, he was less agitated and gave me a little better explanation. During the whole time, my wife and I felt that he talked down to us and treated us as if we were little children who could not understand his explanation. I am trying to decide whether I want to continue on with him.
UofU Patient
March 04, 2016
Very thorough and answered all our questions and offered solutions
UofU Patient
February 20, 2016
Dr. Agarwal spent extra time with us explaining things.
UofU Patient
February 14, 2016
We have already recommended a friend who may be facing prostrate cancer.
UofU Patient
February 13, 2016
It's always the best place to go...............though I freely admit, I wish I didn't have to go there...grin
UofU Patient
January 20, 2016
Providers are always attentive and totally focused on my issues. They never rush through the examination to get to the next patient.
UofU Patient
January 10, 2016
We had and have total confidence in Dr. Agarwal's PA named Julia. She was outstanding.
UofU Patient
January 07, 2016
Great and very professional treatment
UofU Patient
December 13, 2015
good
UofU Patient
December 12, 2015
Dr. Agerwal and staff are amazing, we love and appreciate every one.
UofU Patient
December 10, 2015
I did not understand much the Dr. said, but my wife took good care of explaning for me.
UofU Patient
November 23, 2015
Good
UofU Patient
November 14, 2015
Here the Huntsman Center is unmatchable. Outstanding in every way. I truly feel loved and cared for by Dr. Agarval and his staff. I look forward to seeing them and know, beyond a shadow of a doubt, that everything is fine. I am in the best hands ever. I love them all.
UofU Patient
October 30, 2015
All Good
UofU Patient
October 23, 2015
When my wife ask questions the were answered satisfactory.
UofU Patient
October 23, 2015
Absolute confidence!
UofU Patient
October 20, 2015
As always, our experience with the staff has been wonderful. They are patient with our concerns and questions.
UofU Patient
October 09, 2015
good
UofU Patient
October 04, 2015
Dr. NEERAJ AGARWAL M.D. was extremely helpful and professional.
UofU Patient
September 26, 2015
fortunate to have Dr Agarwal
UofU Patient
September 12, 2015
I love Doctor Agarwal and his staff. I really wouldn't want any other staff caring for me.
UofU Patient
September 08, 2015
He explained my situation in a manner that was easy to understand. His knowledge of my particular case was very good.
UofU Patient
September 03, 2015
Overall it was a good informative experience. I wish now I had come here when first diagnosed.
UofU Patient
August 17, 2015
already have recommended the huntsmen care for others, and from others is where I learned I should go for my own cancer.
UofU Patient
August 07, 2015
I can't think of a better place to help with my cancer and I have already recommended the facility to others
UofU Patient
July 01, 2015
always a good experience. you know what direction you're headed and what to expect. most of all, I recognize I am receiving the best care possible.
UofU Patient
May 11, 2015
Dr Agarwal spent time talking about future treatment without fully explaining the diagnosis. Part of the problem is that he did not take the time to find out what had been explained to me by my previous doctor. He could have asked me, which would have only taken a few minutes, which would have helped him to be much more helpful in explaining both the diagnosis and possible treatment. Also, because my appointment had been changed to 2 days earlier than originally scheduled, making it the same day as the latest CT scan was performed, so one of two reports was unavailable. That might impact the diagnosis.
UofU Patient
May 06, 2015
I have asked a friend in Austin Tx to seek treatment at Huntsman's
UofU Patient
May 01, 2015
we are on the right track with my cancer.
UofU Patient
April 06, 2015
I have the highest confidence in Dr. Agarwal. I feel his commitment to me as a patient has greatly enhanced my quality of life.
UofU Patient
March 19, 2015
We absolutely love Dr. Agarwahl!
UofU Patient
March 10, 2015
good
UofU Patient
February 24, 2015
I had only GOOD experiences!
UofU Patient
February 20, 2015
Dr. Agarwal and his staff are incredible. We have been together one year now and I consider them family. I look forward to seeing everyone: Dr. Agarwal the PA and study coordinator. Despite my personal challenges, they put me at ease and are always encouraging and positive. They are all blessings to me and my family. They have made a difference in my life. I love them all.
UofU Patient
February 17, 2015
Provided great additional information.
UofU Patient
February 17, 2015
I recmmend all of the time
UofU Patient
February 16, 2015
I already conveyed my concerns to patient advocate.
UofU Patient
February 07, 2015
Dr. Neeraj Agarwal spent probably 15 minutes discussing my psa and my future. This was a very good experience.
UofU Patient
January 25, 2015
very good
UofU Patient
January 17, 2015
Alternatives for future care were dumped before me. No evaluation of each, no Dr. recommendations, no assessment that was promised during previous visit were given. Copy of labs, bone scan and CAT scan were handed to me with "very little change" comment. No details were discussed. I was very disappointed with the visit. It seemed a waste of time and insurance dollars. My needs were not considered nor met.
UofU Patient
December 25, 2014
there is no comparison to the care that is recieved at Huntsman.
UofU Patient
December 21, 2014
I know the Nurse Practioner and Doctor were very busy, but they seemed very rushed. I felt that I didn't have enought time to ask the questions in which I needed answers. They answered questions but were very rushed. It wasn't like it was in previous visits.
UofU Patient
December 18, 2014
Doctor Agarwal and his staff have been friendly and courteous from the beginning. Our discussions have been enlightening comforting and at the same time factual. I can say without equivocation I have always felt that Doctor Agarwal and his staff have had my interests at heart
UofU Patient
December 17, 2014
My care provider is indeed concerned about me
UofU Patient
December 10, 2014
good
UofU Patient
November 17, 2014
Awesome staff; caring and professional
UofU Patient
November 17, 2014
good
UofU Patient
November 16, 2014
Dr Agarwal and his staff are excellent.
UofU Patient
November 13, 2014
The Doctor spent over an hour with us as he animatedly shared his "Introduction to Oncology" lecture, tied directly to my current condition.
UofU Patient
November 08, 2014
Very happy with the care provided to me. I don't mind travelling from California to see the doctor here in SLC.
UofU Patient
November 02, 2014
Everyone is always treating me with the utmost care and compassion for my cancer. Treatments are always explained very well and all staff members are the best to work with.
UofU Patient
October 12, 2014
Very knowledgeable and thorough and polite.
UofU Patient
October 06, 2014
Dr Agarwal is excellent.
UofU Patient
September 13, 2014
Great
UofU Patient
September 09, 2014
When my husband (the patient) broke down and cried, the doctor gave him a hug and reassured him.
UofU Patient
September 09, 2014
very confident with the knowledge of my DR and staff
UofU Patient
September 04, 2014
Everything is great.
UofU Patient
August 13, 2014
HUNTSMAN CANCER INSTITUTE is world class!
UofU Patient
August 09, 2014
Dr Agarwal has been wonderful.
UofU Patient
July 25, 2014
Excellent service and Outstanding and Congenial staff as always. I receive the very best care every time I am there. Thank you.
UofU Patient
July 15, 2014
Outstanding
UofU Patient
July 10, 2014
I have a lot of confidence in Doctor Agarwal.
UofU Patient
June 27, 2014
My cancer is stable. IVC and chemo and MindBody has got it stopped.
UofU Patient
June 07, 2014
My cancer is diminishing.
UofU Patient
May 16, 2014
All good Doc.
UofU Patient
May 15, 2014
There was a bit of confusion regarding the reasons for the ordered test due to multiple areas being addressed but this was cleared up with the next providers doing the tests.
UofU Patient
May 14, 2014
Great staff.
UofU Patient
May 10, 2014
Dr. Agarwal is a very knowledgeable, caring professional. I am very fortunate to have him over my care.
UofU Patient
May 10, 2014
Couldn't ask for better
UofU Patient
April 26, 2014
Everytime I visit with Dr. Agarwal, I realize that he is always determining what the next steps are in my treatment program. He is very informative and concerned with my progress. He is sensitive towards my needs as a patient and builds my confidence. His vast knowledge of the disease and forward thinking puts your mind at ease. I always highly recommend Dr. Agarwal to others.
UofU Patient
April 25, 2014
good
UofU Patient
April 14, 2014
Dr. Argawal provided me real answers to my problem and I am very happy to now have him as my doctor. He provided very good explanations and took the time to answer my questions.
UofU Patient
April 13, 2014
Some tech terms but I think I understand
UofU Patient
April 11, 2014
The care providers cound have not been more attnetative to our needs and questions. Everything was explained to us and our input was taken into consideration.
UofU Patient
April 03, 2014
still looking for who my care provider is. as far as I am concerned every one at HCI is my care provider.
UofU Patient
April 02, 2014
Good
UofU Patient
March 30, 2014
Staff know what they are doing and make things easier for family to understand more about my illness.
UofU Patient
March 02, 2014
The staff and doctors were excellent!
UofU Patient
February 22, 2014
Seems like I spend a lot of time at Huntsman. Everyone is always very nice and courteous! I have never had a bad experience! The Valet service is a huge plus especially when you might not be having the best of days! My hat off to everyone!
UofU Patient
February 12, 2014
Dr. Agarwal spent a lot of time outlining different treatment options, most of which were not really an option for me. He also mentioned more than once he had other patients he needed to see. He did ask form one of the Nurses in the IL-2 treatment to come talk with us. She added a lot to what he said. I was called on the following day to let me know about an appointment on that Monday they had scheduled for me in Radiology without having addressed that during my appointment.
UofU Patient
February 12, 2014
Professional, congenial, and clearly caring in every way. I was pampered and treated like a friend or family member. I am convinced my welfare and wellbeing really matters to the folks at HCC
UofU Patient
February 12, 2014
All good
UofU Patient
February 10, 2014
Could not have asked for better people.
UofU Patient
February 07, 2014
Instilled a positive attitude in a stressful situation.
UofU Patient
January 20, 2014
Outstanding
UofU Patient
January 18, 2014
Always perfect.
UofU Patient
January 17, 2014
A lot of variation between Dr, PA and Nurses
UofU Patient
January 13, 2014
Excellent
UofU Patient
January 09, 2014
Outstanding in each of these categories. I did not think the physician and his assistant would have the kind of time for patient I received from both. I felt uniquely special and cared for and about. Thank you to Dr. Agarwal and Julia.
UofU Patient
December 16, 2013
The PA went out of her way to help me understand, She made a graft on the computer to show me the answer a question I had.
UofU Patient
November 20, 2013
They are so good to explaining everything.
UofU Patient
October 28, 2013
We have already recommended Huntsmans to a coworker with a newly diagnosed cancer.
UofU Patient
October 02, 2013
good
UofU Patient
September 20, 2013
care provider made me feel I was the only patient he had.
UofU Patient
August 26, 2013
Every visit I've made to this clinic has always been a good experience.
UofU Patient
August 20, 2013
Dr Agarwal and the nurse practitioners have always been great. They clearly have out best interest at heart and seem invested in us and our progress towards a cure. This time we also saw Steve - pharmacist - he was just as kind as could be and very informative. It is just great how all the disciplines seem to be there, on the spot, when needed.
UofU Patient
August 19, 2013
Dr. Agerwal is the best!!! We love him
UofU Patient
August 08, 2013
Dr. Agerwal is always concerned, kind and willing to answer all questions to our satisfaction.
UofU Patient
July 22, 2013
I am very confident in Dr. Agarwall. He always takes the time to make sure I understand what is going on even though I have been doing whole brain radiation and get confused often.
UofU Patient
July 08, 2013
Again, very impressed and grateful to all.
UofU Patient
June 02, 2013
Everyone was most concerned and helpful.
UofU Patient
May 29, 2013
Great experience
UofU Patient
April 22, 2013
I truly don't know what we would ever do with our Doctor! He is amazing and kind and we know that he truly cares and wants the very best for my husband. He is an amazing man!!!
UofU Patient
April 01, 2013
Every experience I have had at Huntsman has been great. I look forward to driving down from Idaho to not only be treated but vcisit with Doctors and staff. Don't chgange anything.
UofU Patient
March 12, 2013
The visit was very helpful. I felt quite confident about the info.
UofU Patient
March 04, 2013
Dr Agarwal went out of his way to make sure that we understood the risk/reward of the IL 2 therapy, included us in the decision making process, and also welcomed a friend who was sitting on on the session. We left feeling completely confident in the care we would receive from Dr Agarwal and the Nurse practitioners who administer the treatment.
UofU Patient
March 04, 2013
I always feel that everyone is proactively involved in my case and has a personal interest in my progress. I know I am in good hands at the Huntsman.
UofU Patient
February 25, 2013
Narraj is great and is so caring.
UofU Patient
February 25, 2013
As usual. Unbelievable care.
UofU Patient
February 18, 2013
I have recommended and I will continue to recommended my care provider Dr Neeraj Agarwal and his staff to others. I appreciate their committed positive approach to my treatment.
UofU Patient
February 10, 2013
I frequently mention to others about the good experience I have had at HCC. The level of treatment and experience of the doctors is exceptional. The treatment and the facility are world class! Thank you
UofU Patient
January 28, 2013
This visit is the best one I have experienced so far. Keep up the good work.
UofU Patient
January 14, 2013
Pleasantly surprised at the knowledge the provider had of my case upon arrival without looking at notes and the unrushed atmosphere and amount of time spent with me.
UofU Patient
November 27, 2012
We told them about my "flu like" symptoms after my first infusion and they immediately recommended changes in the procedure that would help me to avoid those "flu like" symptoms in the future
UofU Patient
November 12, 2012
Every one is great!!!!!!!!!!
UofU Patient
November 12, 2012
The entire Staff at HCI is on the cutting edge in their profession. I have the highest confidence in their direction and treatment.
UofU Patient
October 29, 2012
If you have Cancer, This is the place to come to for treatment.
UofU Patient
October 22, 2012
Dr. Agarawal was very clear, professional and straightforward in his manner.
UofU Patient
October 12, 2012
I can understand how a Doctor's schedule can be disrupted. I do not understand why I was not better informed of reason for the delay. I certainly do not know why I waited in the Infusion Clinic for nearly 90 minutes because, as I understand, Pharmacy was slow.
UofU Patient
July 30, 2012
I personaly do not like the doctor
UofU Patient
July 16, 2012
We tell everyone this is the best place for excelant care.
UofU Patient
June 26, 2012
Dr. Agarwal is apparently very knowledgeable and proficient medically, but I have found his patient concern and communication skills to be lacking. He demonstrates superficial concern and does a very marginal job of explaining his treatments and taking time to insure that the patient has a comfortable understanding of treatment/changes in treatments. He gives the distinct impression that his "schedule" and clinical studies are much more important that your concerns/comfort level.
UofU Patient
June 25, 2012
they were busy that day but I had no problem
UofU Patient
May 04, 2012
GOOD
UofU Patient
April 13, 2012
thanks for the great care I have been afford in helping me fight my cancer.
UofU Patient
March 23, 2012
Dr. who spoke to us and examined me before Dr. Agarwal was very knowledgeable, and during exam found a potential concern which he told him about.
UofU Patient
March 16, 2012
good
UofU Patient
February 29, 2012
In the three years I have been at the Huntsman Center I can say it has been a pleasant experience and I would highly recommend it to everyone
UofU Patient
February 08, 2012
Good experience
UofU Patient
January 27, 2012
I was well taken care of. I didn't know what to expect. I trust these people to do their best for me.
UofU Patient
January 10, 2012
Very good.
Neeraj Agarwal, MD
Associate Professor, Division of Oncology, Department of Medicine
Neeraj Agarwal, MD, is an Associate Professor in the Division of Oncology, Department of Medicine, at the University of Utah School of Medicine. He is the Director of the Genitourinary Oncology Program in the Oncology Division, the Co-leader of the Urologic Oncology Multidisciplinary Program and the Associate Director of Clinical Trials (solid tumors) at the Huntsman Cancer Institute (HCI).
As a specialist in adult hematology and oncology, Dr. Agarwal cares for patients with all types of cancer and specializes in genitourinary malignancies (cancers of the prostate, kidney, bladder and testes).
Dr. Agarwal is a member of several professional societies, including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR) and the Southwest Oncology Group (SWOG). After receiving his MD degree from All India Institute of Medical Sciences in New Delhi, India, Dr. Agarwal completed a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa. He then completed a hematology-oncology fellowship at HCI and the University of Utah School of Medicine.
Dr. Agarwal has received several awards and grants and has authored more than 150 peer-reviewed articles and book chapters. He has given talks at several prestigious regional and national forums, including the workshop at the National Institute of Health’s National Institute on Aging, Utah Urologic Society Annual meeting, and MD Anderson Cancer Center’s–sponsored oncology conferences. He serves as a panel member for the National Comprehensive Cancer Network (NCCN) guideline- committees for bladder, kidney cancer and testicular cancer. Dr. Agarwal also serves as the national principle investigator and chair of a National Cancer Institute (NCI) funded multicenter phase III clinical trial for men with newly diagnosed metastatic prostate cancer. This trial is sponsored by SWOG, one of the largest National Cancer Institute’s (NCI) clinical trials group, and endorsed by all major groups in NCI Clinical Trials Network ( ECOG, CALGB etc.). This trial is expected to recruit more than 1500 men with newly diagnosed metastatic prostate cancer across the United States. In addition, he is the Principal Investigator (PI) for three investigator-initiated clinical trials for men with prostate cancer, along with being a site PI for multiple other industry and cooperative group trials.
Dr. Agarwal has the prestigious honor of being chosen as one of the five young investigators of the Southwest Oncology Group in 2009. He has been appointed as the leader of early therapeutics of the SWOG Genitourinary Cancer Committee in 2010. Dr. Agarwal is also the recipient of the prestigious 2009-2010 William D. Odell Young Investigator award from the University of Utah’s, Department of Medicine, and the 2014 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.
Academic Locations
Huntsman Cancer Institute
801-587-4642
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Medical Oncology) American Board of Internal Medicine (Sub: Geriatric Medicine) |
| Cancer Center Programs | Experimental Therapeutics |
Education History
| Fellowship | University of Utah School of Medicine Hematology/Oncology Fellow |
| Fellowship | University of Iowa Hospitals and Clinics Geriatrics Fellow |
| Residency | University of Iowa Hospitals and Clinics Internal Medicine Resident |
| Internship | Advocate Illinois Masonic Medical Center Internal Medicine Intern |
| Professional Medical | All India Institute of Medical Sciences Medicine M.D. |
| Professional Medical | Assam Medical College Medicine M.B.B.S. |
Publications - Journal Articles
Journal Article
- Gill DM, Agarwal N, Vaishampayan U (2017). Evolving Treatment Paradigm in Metestatic Renal Cell Carcinoma. PMID: 28561652. American Society of Clinical Oncology Educational Book.
- Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R (2017). Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(6), 804-834.
- Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH (2017). Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.LID - S0302-2838(17)30467-0 [pii]LID - 10.1016/j.eururo.2017.05.033 [doi]. (Epub ahead of print) Eur Urol.
- Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN Jr, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM Jr, Twardowski PW, Van Veldhuizen PJ Jr, Agarwal N, Carducci MA, Monk JP, Quinn DI (2017). Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.LID - S1558-7673(17)30138-6 [pii]LID - 10.1016/j.clgc.2017.05.014 [doi]. (Epub ahead of print) Clin Genitourin Cancer.
- Gill DM, Sonpavde G, Pal SK, Agarwal N (2017). Which checkpoint inhibitor? An embarrassment of riches for bladder cancer. Immunotherapy, 9(6), 463-466.
- Maughan BL, Bailey E, Gill DM, Agarwal N (2017). Incidence of Immune-Related Adverse Events with Program Death Receptor-1-and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers. Frontiers in Oncology, 7, 56.
- Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal SK, Stenehjem DD, Agarwal N (2017). Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. J Oncol Pharm Pract, 1078155217693426.
- Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman RB, Banks KC, Choueiri TK (2017). Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.LID - S0302-2838(17)30277-4 [pii]LID - 10.1016/j.eururo.2017.03.046 [doi]. (Epub ahead of print) Eur Urol.
- Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC (2017). Characterizing the outcomes of metastatic papillary renal cell carcinoma.LID - 10.1002/cam4.1048 [doi]. (Epub ahead of print) Cancer Med.
- Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal N (2017). Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.LID - 10.18632/oncotarget.16833 [doi]. (Epub ahead of print) Oncotarget.
- Hansberry DR, Donovan AL, Prabhu AV, Agarwal N, Cox M, Flanders AE (2017). Enhancing the Radiologist-Patient Relationship through Improved Communication: A Quantitative Readability Analysis in Spine Radiology.LID - 10.3174/ajnr.A5151 [doi]. (Epub ahead of print) AJNR Am J Neuroradiol.
- Flaig TW, Plets M, Hussain MH, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM Jr (2017). Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.LID - 10.1001/jamaoncol.2017.0231 [doi]. (Epub ahead of print) JAMA Oncol.
- Clark JI, Wong MK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S (2017). Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clin Genitourin Cancer, 15(1), 31-41.e4.
- Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N (2017). Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urol, 17(1), 1.
- Narayan V, Keefe SM, Haas N, Wang L, Puzanov I, Putt ME, Catino A, Fang J, Agarwal N, Hyman D, Smith AM, Finkelman BS, Narayan HK, Ewer S, ElAmm C, Lenihan DJ, Ky B (2017). Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma.LID - clincanres.2869.2016 [pii]LID - 10.1158/1078-0432.CCR-16-2869 [doi]. (Epub ahead of print) Clin Cancer Res.
- De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DY, Choueiri TK (2017). Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.LID - S1558-7673(17)30005-8 [pii]LID - 10.1016/j.clgc.2017.01.005 [doi]. (Epub ahead of print) Clin Genitourin Cancer.
- Gupta S, Greenberg S, Grimmett J, Gaston D, Agarwal N, Lowrance W, Schiffman J, Kohlmann W (2017). Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers.LID - 10.1007/s10689-017-9980-2 [doi]. (Epub ahead of print) Fam Cancer.
- Motzer RJ, Figlin RA, Martini JF, Hariharan S, Agarwal N, Li CX, Williams JA, Hutson TE (2017). Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial.LID - S1558-7673(17)30049-6 [pii]LID - 10.1016/j.clgc.2017.02.006 [doi]. (Epub ahead of print) Clin Genitourin Cancer.
- Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, Bjarnason GA, Yamamoto H, Beuselinck B, Rini BI, Knox JJ, Agarwal N, Ernst DS, Pal SK, Wood LA, Bamias A, Alva AS, Kanesvaran R, Choueiri TK, Heng DY (2017). Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol, 71(2), 204-209.
- Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY (2017). Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Med, 6(1), 186-194.
- Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ (2017). Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.LID - S1558-7673(16)30351-2 [pii]LID - 10.1016/j.clgc.2016.12.005 [doi]. (Epub ahead of print) Clin Genitourin Cancer.
- Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L (2017). Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol, 71(2), 281-289.
- Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DYC (2017). Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol, 71(6), 970-978.
- Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung, Higano CS (2017). Reply to M.A.N. Sendur et al and J. Michels. J Clin Oncol, 35(1), 123.
- Parker SJ, Pond GR, Agarwal N, Alex A, Heilbrun ME, Sonpavde G (2017). Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer, 15(1), 53-59.
- Albright FS, Stephenson RA, Agarwal N, Cannon-Albright LA (2017). Relative Risks for Lethal Prostate Cancer Based on Complete Family History of Prostate Cancer Death. Prostate, 77(1), 41-48.
- Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal N (2017). Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.LID - S1558-7673(16)30354-8 [pii]LID - 10.1016/j.clgc.2016.12.008 [doi]. (Epub ahead of print) Clin Genitourin Cancer.
- Agarwal N, Hahn AW, Gill DM, Farnham JM, Poole AI, Cannon-Albright L (2017). Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.LID - 10.1001/jamaoncol.2017.0147 [doi]. (Epub ahead of print) JAMA Oncol.
- Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N (2016). Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience, 10, 676.
- Dahal A, Bellows BK, Sonpavde G, Tantravahi SK, Choueiri TK, Galsky MD, Agarwal N (2016). Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis. Am J Clin Oncol, 39(5), 497-506.
- Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R (2016). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res, 22(8), 1932-9.
- Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother Pharmacol, 77(2), 299-308.
- Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Pal S, Eigl BJ (2016). Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. Clin Genitourin Cancer, 14(4), 331-40.
- Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, Redman B, Agarwal N, Alva A (2016). Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunol Immunother, 65(8), 941-9.
- Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DY, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ (2016). Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol, 17(7), 917-27.
- Gill D, Hahn AW, Sonpavde G, Agarwal N (2016). Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Hum Vaccin Immunother, 12(12), 2997-3004.
- Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP (2016). Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother, 65(12), 1533-1544.
- Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal N (2016). A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer Chemother Pharmacol, 78(5), 1059-1071.
- Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal N (2016). Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clin Genitourin Cancer, 14(2), 153-9.
- Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen EM, Krajewski KM, Porta C, Pal SK, Bellmunt J, McDermott DF, Heng DY, Gray KP, Signoretti S (2016). Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res, 22(10), 2445-52.
- Pal SK, Agarwal N (2016). Kidney cancer: Finding a niche for girentuximab in metastatic renal cell carcinoma. Nat Rev Urol, 13(8), 442-3.
- Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clark PE, Plimack ER (2016). National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol, 34(27), 3346-8.
- Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK (2016). Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.LID - JCO667311 [pii]. (Epub ahead of print) J Clin Oncol.
- Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C (2016). NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw, 14(10), 1213-1224.
- Pal SK, Agarwal N, Dizman N, Sonpavde G (2016). Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar. Lancet Oncol, 17(11), 1477-1478.
- Agarwal N, Shuch B, Pal SK (2016). Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in Treatment-Naive Patients With Metastatic Renal Cell Carcinoma. JAMA Oncol, 2(10), 1273-1274.
- Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS (2016). Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J Clin Oncol, 34(18), 2098-106.
- Agarwal N, Machiels JP, Suarez C, Lewis N, Higgins M, Wisinski K, Awada A, Maur M, Stein M, Hwang A, Mosher R, Wasserman E, Wu G, Zhang H, Zieba R, Elmeliegy M (2016). Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. Oncologist, 21(5), 535-6.
- Agarwal N, Alex AB, Farnham JM, Patel S, Gill D, Buckley TH, Stephenson RA, Cannon-Albright L (2016). Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer. J Urol, 196(4), 1112-6.
- Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bogemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartsmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M (2016). Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol, 34(22), 2636-43.
- Pal SK, Vuong W, Zhang W, Deng J, Liu X, Carmichael C, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin RA, Agarwal N, Jones JO (2015). Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer. Mol Cancer Ther, 14(12), 2896-900.
- Campo RA, Light KC, OConnor K, Nakamura Y, Lipschitz D, LaStayo PC, Pappas LM, Boucher KM, Irwin MR, Hill HR, Martins TB, Agarwal N, Kinney AY (2015). Blood pressure, salivary cortisol, and inflammatory cytokine outcomes in senior female cancer survivors enrolled in a tai chi chih randomized controlled trial. J Cancer Surviv, 9(1), 115-25.
- Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI (2015). Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer, 136(8), 1856-62.
- Albright F, Stephenson RA, Agarwal N, Teerlink CC, Lowrance WT, Farnham JM, Albright LA (2015). Prostate cancer risk prediction based on complete prostate cancer family history. Prostate, 75(4), 390-8.
- Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G (2015). Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. Clin Genitourin Cancer, 13(2), 178-84.
- Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI (2015). Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer, 13(2), e79-85.
- Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, Torres A, Hernandez S, Lau C, Agarwal N, Kawachi M, Yen Y, Jones JO (2015). Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. Clin Genitourin Cancer, 13(2), 130-6.
- Fay AP, Xie WL, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishamayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, Choueiri TK, Heng DY (2015). Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. Clin Genitourin Cancer, 13(2), 150-5.
- Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD, Agarwal N (2015). Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clin Genitourin Cancer, 13(3), e131-7.
- Reese Z, Straubhar A, Pal SK, Agarwal N (2015). Ipilimumab in the treatment of prostate cancer. Future Oncol, 11(1), 27-37.
- Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY (2015). Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis, 18(2), 122-7.
- Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R (2015). Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol, 33(7), 723-31.
- Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY (2015). The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol, 16(3), 293-300.
- Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, Stenehjem DD, Agarwal N (2015). Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. J Oncol, 2015, 181926.
- Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R (2015). Kidney cancer, version 3.2015. J Natl Compr Canc Netw, 13(2), 151-9.
- Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr (2015). SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol, 33(14), 1601-8.
- Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE (2015). Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer, 121(15), 2586-93.
- Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (2015). Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs, 33(3), 691-9.
- Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R (2015). Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw, 13(6), 772-99.
- Singh P, Pal SK, Alex A, Agarwal N (2015). Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol, 11(15), 2137-48.
- Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM (2015). FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging, 15, 15.
- Werner TL, Wade ML, Agarwal N, Boucher K, Patel J, Luebke A, Sharma S (2015). A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-beta, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Invest New Drugs, 33(6), 1217-24.
- Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC (2014). A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer, 120(17), 2684-93.
- Agarwal N, Dorff T, Goldkorn A (2014). New prostate cancer drugs: extending and improving life. Lancet Oncol, 15(10), 1052-4.
- Alwan LM, Grossmann K, Sageser D, Van Atta J, Agarwal N, Gilreath JA (2014). Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target Oncol, 9(1), 63-71.
- Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD (2014). Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev, 40(1), 190-6.
- Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD (2014). Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol, 9(3), 195-204.
- Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY (2014). Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol, 65(6), 1086-92.
- Campo RA, Agarwal N, LaStayo PC, OConnor K, Pappas L, Boucher KM, Gardner J, Smith S, Light KC, Kinney AY (2014). Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong. J Cancer Surviv, 8(1), 60-9.
- Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S (2014). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res, 20(2), 480-9.
- Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, Choueiri TK (2014). The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol, 65(4), 723-30.
- Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, ODonnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G (2014). A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int, 113(5b), E137-43.
- Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G (2014). Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 12(2), 130-7.
- Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood LA (2014). Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol, 25(1), 149-54.
- Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R (2014). Kidney cancer, version 2.2014. J Natl Compr Canc Netw, 12(2), 175-82.
- Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ (2014). Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol, 32(11), 1136-42.
- Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY (2014). First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer, 110(8), 1917-22.
- Cannon-Albright LA, Farnham JM, Bailey M, Albright FS, Teerlink CC, Agarwal N, Stephenson RA, Thomas A (2014). Identification of specific Y chromosomes associated with increased prostate cancer risk. Prostate, 74(9), 991-8.
- Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR (2014). Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol, 15(7), 700-12.
- Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK (2014). Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol, 66(4), 704-10.
- Agarwal N, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD (2014). Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma. Oncologist, 19(9), 915-6.
- Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T (2014). Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother, 37(7), 360-5.
- Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, MacKenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY (2013). The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol, 8(3), 203-9.
- Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK (2013). External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol, 14(2), 141-8.
- Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G (2013). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 11(3), 316-20.
- Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M (2013). Bladder cancer. J Natl Compr Canc Netw, 11(4), 446-75.
- Campo RA, OConnor K, Light KC, Nakamura Y, Lipschitz DL, LaStayo PC, Pappas L, Boucher K, Irwin MR, Agarwal N, Kinney AY (2013). Feasibility and acceptability of a Tai Chi Chih randomized controlled trial in senior female cancer survivors. Integr Cancer Ther, 12(6), 464-74.
- Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M (2013). Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 11(5), 594-615.
- Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY (2013). Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer, 119(16), 2999-3006.
- Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G (2013). Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer, 11(4), 495-500.
- Birmingham WC, Agarwal N, Kohlmann W, Aspinwall LG, Wang M, Bishoff J, Dechet C, Kinney AY (2013). Patient and provider attitudes toward genomic testing for prostate cancer susceptibility: a mixed method study. BMC Health Serv Res, 13, 279.
- Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr (2013). Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol, 14(9), 893-900.
- Nelson Q, Agarwal N, Stephenson R, Cannon-Albright LA (2013). A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer. Front Genet, 4, 152.
- Light KC, Agarwal N, Iacob E, White AT, Kinney AY, VanHaitsma TA, Aizad H, Hughen RW, Bateman L, Light AR (2013). Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome. Psychoneuroendocrinology, 38(12), 2983-95.
- Swierczek S, Agarwal AM, Naidoo K, Lorenzo FR, Whisenant J, Nussenzveig RH, Agarwal N, Coetzer TL, Prchal JT (2013). Novel exon 2 alpha spectrin mutation and intragenic crossover: three morphological phenotypes associated with four distinct alpha spectrin defects. Haematologica, 98(12), 1972-9.
- Kunkalla K, Liu Y, Qu C, Leventaki V, Agarwal NK, Singh RR, Vega F (2013). Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype. Ann Hematol, 92(6), 777-87.
- Swierczek SI, Piterkova L, Jelinek J, Agarwal N, Hammoud S, Wilson A, Hickman K, Parker CJ, Cairns BR, Prchal JT (2012). Methylation of AR locus does not always reflect X chromosome inactivation state. Blood, 119(13), e100-9.
- Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA (2012). Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol, 30(12), 1371-7.
- Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB (2012). Testicular cancer. J Natl Compr Canc Netw, 10(4), 502-35.
- Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK (2012). Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol, 13(9), 927-35.
- Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG (2012). A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw, 10(11), 1391-8.
- Montejo ME, Shrieve DC, Bentz BG, Hunt JP, Buchman LO, Agarwal N, Hitchcock YJ (2011). IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys, 81(5), e845-52.
- Agarwal N, Sonpavde G, Sartor O (2011). Cabazitaxel for the treatment of castration-resistant prostate cancer. Future Oncol, 7(1), 15-24.
- Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB (2011). Kidney cancer. J Natl Compr Canc Netw, 9(9), 960-77.
- Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J (2009). NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw, 7(6), 672-93.
- Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J (2009). NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw, 7(6), 618-30.
- Agarwal N, Batten J (2009). Optimal treatment in the postorchiectomy management of clinical stage I seminoma. Oncology (Williston Park), 23(9), 764, 767.
- Agarwal N, Prchal JT (2009). Anemia of chronic disease (anemia of inflammation). Acta Haematol, 122(2-3), 103-8.
- Lim HY, Werner TL, Agarwal N, Rodgers GM (2008). Management of Thrombotic Microangiopathy with Underlying Malignancy. Review Series - Oncology, 12(2), 18-21.
- Anderson M, Hartz A, Nordin T, Rosenbaum M, Noyes R, James P, Ely J, Agarwal N, Anderson S (2008). Community physicians' strategies for patients with medically unexplained symptoms. Fam Med, 40(2), 111-8.
- Swierczek SI, Agarwal N, Nussenzveig RH, Rothstein G, Wilson A, Artz A, Prchal JT (2008). Hematopoiesis is not clonal in healthy elderly women. Blood, 112(8), 3186-93.
- Agarwal N, Mojica-Henshaw MP, Simmons ED, Hussey D, Ou CN, Prchal JT (2007). Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia. Int J Med Sci, 4(4), 232-6.
- Agarwal N, Kutlar F, Mojica-Henshaw MP, Ou CN, Gaikwad A, Reading NS, Bailey L, Kutlar A, Prchal JT (2007). Missense mutation of the last nucleotide of exon 1 (G->C) of beta globin gene not only leads to undetectable mutant peptide and transcript but also interferes with the expression of wild allele. Haematologica, 92(12), 1715-6.
- Nordin TA, Hartz AJ, Noyes R Jr, Anderson MC, Rosenbaum ME, James PA, Ely JW, Agarwal N, Levy BT (2006). Empirically identified goals for the management of unexplained symptoms. Fam Med, 38(7), 476-82.
- Agarwal N, Handa R, Acharya SK, Wali JP, Dinda AK, Aggarwal P (2001). A study of autoimmune markers in hepatitis C infection. Indian J Med Res, 113, 170-4.
Review
- Gupta S, Gill D, Poole A, Agarwal N (2017). Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions.LID - E15 [pii]LID - 10.3390/cancers9020015 [doi]. [Review]. Cancers (Basel), 9(2).
- Alex AB, Pal SK, Agarwal N (2016). CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. [Review]. Ther Adv Med Oncol, 8(4), 267-75.
- Singh P, Agarwal N, Pal SK (2015). Sequencing systemic therapies for metastatic kidney cancer. [Review]. Curr Treat Options Oncol, 16(1), 316.
- Gupta S, Gill D, Pal SK, Agarwal N (2015). Activin receptor inhibitors--dalantercept. [Review]. Curr Oncol Rep, 17(4), 14.
- Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J (2014). New agents for prostate cancer. [Review]. Ann Oncol, 25(9), 1700-9.
- Zhang TY, Agarwal N, Sonpavde G, DiLorenzo G, Bellmunt J, Vogelzang NJ (2013). Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. [Review]. Curr Urol Rep, 14(3), 174-83.
- Patel JC, Maughan BL, Agarwal AM, Batten JA, Zhang TY, Agarwal N (2013). Emerging molecularly targeted therapies in castration refractory prostate cancer. [Review]. Prostate Cancer, 2013, 981684.
- Agarwal N, Hussain M (2013). Management of hormone-sensitive metastatic prostate cancer. [Review]. Hematol Oncol Clin North Am, 27(6), 1221-41, viii.
- Agarwal N, Sonpavde G, Sternberg CN (2012). Novel molecular targets for the therapy of castration-resistant prostate cancer. [Review]. Eur Urol, 61(5), 950-60.
- Agarwal N, Padmanabh S, Vogelzang NJ (2012). Development of novel immune interventions for prostate cancer. [Review]. Clin Genitourin Cancer, 10(2), 84-92.
- Agarwal N, Vogelzang NJ (2012). Beyond the abstract- Development of novel immune interventions for prostate cancer. [Review]. UroToday International Journal, UroToday.
- Fishman M, Hutson T, Agarwal N, Jonasch E (2012). Paradigm towards Tailored Therapies and Complete Responses in the Treatment of Metastatic Renal Cell Carcinoma. [Review]. Oncology & Hematology Review, 8(1): 30-8.
- Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW (2011). Recent advances in immunotherapy for the treatment of prostate cancer. [Review]. Expert Opin Biol Ther, 11(8), 997-1009.
- Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G (2010). Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. [Review]. Future Oncol, 6(5), 665-79.
- Agarwal N, Hussain M (2009). Management of bladder cancer: current and emerging strategies. [Review]. Drugs, 69(9), 1173-87.
- Agarwal N, Prchal JT (2008). Erythropoietic agents and the elderly. [Review]. Semin Hematol, 45(4), 267-75.
- Werner TL, Agarwal N, Carney HM, Rodgers GM (2007). Management of cancer-associated thrombotic microangiopathy: what is the right approach? [Review]. Am J Hematol, 82(4), 295-8.
- Agarwal N, Spahr JE, Rodgers GM (2007). Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa. [Review]. Blood Coagul Fibrinolysis, 18(2), 205-7.
- Agarwal N, Gordeuk RV, Prchal JT (2007). Genetic mechanisms underlying regulation of hemoglobin mass. [Review]. Adv Exp Med Biol, 618, 195-210.
Book Chapter
- Gupta S, Agarwal N (2016). Cancer Immunotherapy with Interleukin-2-Current Status and Future Developments. In Katrina Mountfort (Ed.), Oncology & Hematology Review (12, pp. 82-8).
- Singh P, Albertson D, Pal SK, Agarwal N (2016). Mucinous, Signet Ring, Ductal, and Sarcomatoid Variants of Prostate Cancer. In Lance Pagliaro (Ed.), Rare Genitourinary Tumors (First Edition). New York: Springer.
- Poole A, Alva A, Batten JA, Agarwal N (2014). Metastatic Castrate Resistant Prostate cancer: Role of Androgen Signaling Inhibitors. In Dicker AP, Trabulsi EJ, Kelly W (Eds.), Multidisciplinary Approach to Prostate Cancer. New York: Demos Medical Publishing.
- Agarwal N, Fishman M (2014). Immunologic Therapy of Renal Cell Carcinoma. In Oncology & Hematology Review (10, pp. 54-60).
- Kollepara SS, Tantravahi SK, Batten J, Agarwal N (2013). Integrating Emerging Science into Clinical Practice:Targeting Androgen Signaling in Castration Resistant Metastatic Prostate Cancer”. In Lopaczynski W, Srivastava R, and Maksymowicz W. (Eds.), Lost in Translation: Barriers in Incentives for Translational Research. Singapore: World Scientific Publishing Co Pte. Ltd.
- Agarwal N, Vogelzang NJ (2012). Beyond the abstract- Development of novel immune interventions for prostate cancer. In UroToday. UroToday.com.
- Fishman M, Hutson T, Agarwal N, Jonasch E (2012). Paradigm towards Tailored Therapies and Complete Responses in the Treatment of Metastatic Renal Cell Carcinoma. In Oncology & Hematology Review (8, pp. 30-8).
- Agarwal N, Vogelzang NJ (2011). Development of novel immune interventions for genitor-urinary cancers. In Adrian Bot, Mihail Obrocea & Francesco Marincola (Eds.), Cancer Vaccines (1st Edition). London, UK: Informa Healthcare.
- Agarwal N, Prchal JT (2009). Methemoglobinemia and Other Dyshemoglobinemias. In Kaushansky K, Lichtman M, Beutler E, et al. (Eds.), Williams Hematology (8th edition). New York: McGraw-Hill.
- Agarwal N, Gordeuk VR, Prchal JT (2009). Genetic Mechanisms Underlying Regulation of Hemoglobin Mass. In Roach RC, Wagner PD, and Hackett PH (Eds.), Hypoxia and Circulation (2007, pp. 195-210). New York: Springer.
- Agarwal N, Rodgers GM (2009). Miscellaneous Causes of Thrombocytopenia. In Greer JP, Foerster J, Rodgers GM et al. (Eds.), Wintrobe's Clinical Hematology (Edition 12, 2, pp. 1326-1334). Lippincott Williams & Wilkins.
- Agarwal N, Prchal JT (2009). Dyshemoglobinemia. In Steinberg MH, Forget BG, Higgs DR, Nagel RL (Eds.), Disorders of Hemoglobin, Genetics, Pathophysiology, and Clinical Management (2nd ed, pp. 607-622). New York: Cambridge University Press.
- Lim HY, Werner TL, Agarwal N, Rodgers GM (2008). Management of Thrombotic Microangiopathy with Underlying Malignancy. In Review Series Oncology (12, pp. 18-21).
- Agarwal N, Gordeuk VR, Prchal JT (2007). Genetic Mechanisms Underlying Regulation of Hemoglobin Mass. In Roach RC, Wagner PD, and Hackett PH (Eds.), Hypoxia and Circulation. New York: Springer.
Case Report
- Merriman J, Tward J, Albertson D, Dechet C, Agarwal N (2016). Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma. J Immunother, 39(2), 101-3.
- Sangle NA, Mao R, Shetty S, Schiffman JD, Dechet C, Layfield L, Agarwal N, Liu T (2013). Novel molecular aberrations and pathologic findings in a tubulocystic variant of renal cell carcinoma. Indian J Pathol Microbiol, 56(4), 428-33.
- Narayanan S, Callis-Duffin K, Batten J, Agarwal N (2010). Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci, 339(6), 580-1.
- Lim HY, Agarwal AM, Agarwal N, Ward JH (2009). Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J, 50(5), e178-80.
- Agarwal AM, Agarwal N, Glenn MJ, Lim MS (2007). Blastic transformation of low-grade follicular lymphoma. J Clin Oncol, 25(16), 2326-8.
- Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM (2006). Acquired amegakaryocytic thrombocytopenic purpura. Am J Hematol, 81(2), 132-5.
- Agarwal N, Cherascu B (2002). Concomitant acral necrosis and haemolytic uraemic syndrome following ingestion of quinine. J Postgrad Med, 48(3), 197-8.
- Sharma S, Dey AB, Agarwal N, Nagarkar KM, Gujral S (1999). Tuberculosis: a rare cause of splenic abscess. J Assoc Physicians India, 47(7), 740-1.
Editorial
- Pal SK, Maia MC, Dizman N, Agarwal N (2017). Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma?LID - S0302-2838(17)30171-9 [pii]LID - 10.1016/j.eururo.2017.03.006 [doi]. Eur Urol.
- Pal SK, Agarwal N, Grivas P, Choueiri T (2016). Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence. J Clin Oncol, 34(8), 777-9.
- Agarwal N, Sonpavde G, Choueiri TK, Pal SK (2016). Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. Eur Urol, 70(1), 42-4.
- Pal SK, Karam JA, Bergerot P, Agarwal N (2016). Developing a Clear Path Forward for Non-Clear-Cell Renal Carcinoma.LID - JCO693572 [pii]. J Clin Oncol.
- Pal SK, Agarwal N, Jones JO (2015). Circulating tumor cells in prostate cancer: Does (nuclear) size matter? Cancer, 121(18), 3190-2.
- Agarwal N, Vogelzang NJ (2011). Secondary hormonal manipulations in the treatment of castration refractory prostate cancer. BJU Int, 108(2), 227-8.
- Agarwal N (2011). Editorial comment. J Urol, 186(3), 887; author reply 888.
Letter
- Agarwal N (2010). Hormonal therapy for prostate cancer in men with heart disease [Letter to the editor]. JAMA, 303(1), 32-3; author reply 33.
- Chen A, Agarwal N (2009). Reversible posterior leucoencephalopathy syndrome associated with sunitinib [Letter to the editor]. Intern Med J, 39(5), 341-2.
- Agarwal N, Nussenzveig RH, Swierczek SI, Parker CJ, Prchal JT (2009). Does HUMARA assay for assessment of clonal hematopoiesis have shortcomings? [Letter to the editor]. Blood, 114(11), 2357-8; author reply 2358-9.
- Yoon D, Agarwal N, Prchal JT (2008). Does erythropoietin promote tumor growth? [Letter to the editor]. Clin Cancer Res, 14(6), 1920; author reply 1920-1.
- Wada DA, Agarwal N, Florell SR, Lim MS (2008). Recurrent squamous cell carcinoma and follicular lymphoma arising in the scalp after treatment for lymphoma [Letter to the editor]. Pathology, 40(3), 316-20.
- Agarwal N, Gordeuk VR, Prchal JT (2007). Are erythropoietin receptors expressed in tumors? Facts and fiction--more careful studies are needed [Letter to the editor]. J Clin Oncol, 25(13), 1813-4; author reply 1815.
- Agarwal N, Fletcher D, Ward J (2007). Obesity and treatment of prostate cancer: what is the right dose of Lupron Depot? [Letter to the editor]. Clin Cancer Res, 13(13), 4027.
- Agarwal N, Tepe EM, Mishra A, Ward JH (2006). Relapse of acute promyelocytic leukemia presenting as granulocytic sarcoma in the hip [Letter to the editor]. Ann Hematol, 85(10), 741-2.
- Agarwal N, Klix MM, Burns CP (2004). Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance [Letter to the editor]. Ann Intern Med, 141(1), 83-4.
Abstract
- Michaelson MD, Gupta S, Agarwal N, Szmulewitz RZ, Powles T, Pili R, Bruce JY, Vaishampayan UN, Larkin JMG, Rosbrook B, Lechuga M, Valota O, Tarazi JC, Shepard DR (2017). Axitinib plus crizotinib in patiens with advanced solid tumors and metastatic renal cell carcinoma (mRCC): Preliminary phase 1b results [Abstract]. Journal of Clinical Oncology.
- De Bono JS, Hussain M, Thiery-Vuillemin A, Mateo J, Sartor AO, Chi KN, Fizazi K, Twardowski P, Agarwal N, Sandhu SK, Olmos D, Shore ND, Saad F, Liu S, Goessl CD, Burgents J (2017). PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration [Abstract]. Journal of Clinical Oncology.
- Agarwal N, Heemers H, Farnham JM, Patel SB, Gill DM, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright LA (2016). Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 5066).
- Nagy RJ, Agarwal N, Gupta S, Pal SK, Grivas P, Vaishampayan UN, Wang J, Naik G, Lanman RB, Talasaz A, Sonpavde G (2016). Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma of the bladder. Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 4528).
- Sonpavde G, Nagy RJ, Agarwal N, Gourdin TS, Naik G, Eshaghian S, Wang J, Armstrong AJ, Vaishampayan UN, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB (2016). Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 5035).
- Pond GR, Sonpavde G, Plets M, Tangen CM, Hussain M, Lara P, Goldkorn A, Garzotto M, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk P, Quinn DI (2016). Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421. Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 5079).
- Alex A, Stenehjem DD, Twardowski P, Cheng HH, Gill DM, Buckley H, Patel SB, Kessler ER, Chittoria N, Poudel A, Vaishampayan UN, Agarwal N (2016). Impact of prior definitive therapy on survival outcomes in men with new hormone-sensitive metastatic prostate cancer (mHSPC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 5083).
- Sonpavde G, Nelson RA, Trinh Q, Agarwal N, Nix J, Kardos S, Bellmunt J, Choueiri TK, Pal SK (2016). Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 4524).
- Wells JC, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Knox JJ, Beuselinck B, Rha SY, Agarwal N, Brugarolas J, Lee JL, Pal SK, Srinivas S, Ernst DS, Vaishampayan UN, Wood L, Simpson R, Velasco G, Choueiri TK, Heng DYC (2016). Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 4554).
- Agarwal N, Tagawa ST, Chatta GS, Pal SK, Goel S, Mazhari R, Heaton C, Benaim E (2016). Results from a phase 1b/2 study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma. Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 2559).
- Goldkorn A, Plets M, Agarwal N, Hussain M, Lara P, Vaena DA, MacVicar GR, Crispino T, Harzstark AL, Twardowski P, Tangen CM, Hugen CM, Xu T, Xu Y, Pinski JK, Ingles SA, Higano CS, Vogelzang NJ, Thompson IM, Quinn DI (2016). Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 11516).
- Bergerot PG, Sonpavde G, Nelson RA, Agarwal N, Costa CN, Hsu J, Choueiri TK, Pal SK (2016). Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): An updated report using the National Cancer Database (NCDB). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL [Abstract]. J Clin Oncol 34, 2016 (suppl; abstr 4540).
- Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD (2016). Effect of concomitant proton pump inhibitor (PPI) on effectiveness of tyrosine kinase inhibitor (TKI) in patients with metastatic renal cell carcinoma (mRCC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 608).
- Parker SJ, Pond GR, Sonpavde G, Alex A, Heilbrun ME, Agarwal N (2016). Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 191).
- Bergerot PG, Nelson RA, Ye DW, Grivas P, Singh P, Agarwal N, Choueiri TK, Pal SK (2016). Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic magnancies. Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 363).
- Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD (2016). Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 610).
- Sonpavde G, Nagy RJ, Apolo AB, Agarwal N, Pal SK, Grivas P, Vaishampayan UN, Lanman RB, Talasaz A (2016). Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma. Oral Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 358).
- Alex A, Stenehjem DD, Twardowski P, Cheng HH, Buckley TH, Gill D, Patel SB, Vaishampayan UN, Agarwal N (2016). Impact of prior definitive therapy on survival outcomes in men with new hormone sensitive metastatic prostate cancer (mHSPC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 269).
- Gill D, Alex A, Farnham JM, Buckley TH, Patel SB, Agarwal AM, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA, Agarwal N (2016). Association of single nucleotide polymorphism in four genes and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive prostate cancer (aHSPC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 224).
- Buckley TH, Alex A, Farnham JM, Gill D, Patel SB, Teerlink C, Albright FS, Stephenson, RA, Cannon-Albright LA, Agarwal N (2016). Assiciation of single nucleotide polymorphisms (SNPs) in SULT1E1 with response to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 222).
- Li H, Kroeger N, deVelasco G, Donskov F, Sim HW, Wells C, Stukalin I, Agarwal N, Parekh HD, Rini BI, Knox JJ, Pantuck AJ, Choueiri TK, Heng DYC (2016). The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy. Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 552).
- Escudier BJ, Motzer RJ, Powles T, Tannir NM, Davis ID, Donskov F, Grunwald V, Heng DYC, Hutson T, Melichar B, Nosov D, Rini BI, Salman P, Sternberg CN, Szczylik C, Wolter P, Arroyo AM, Mangeshkar M, Agarwal N, Choueiri TK (2016). Subgroup analysis of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 499).
- Ramos, J, Wong YN, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, Hussain SA, Baniel J, Golshayan AR, Powles T, Rosenberg JE, Giorgi UD, Vaishampayan UN, Agarwal N, Pal SK, Harshman LC, Necchi A, Recine F, Galsky MD, Yu EY, RISC Investigators (2016). Venous thromboembolism (VTE) risk in patients with localized urinary tract tumors (UTT). Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 422).
- Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood L, Kollmannsberger CK, Rha SY, North SA, Kanesvaran R, Rini BI, Broom RJ, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK (2016). DiscontinuingVEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC). Oral Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 503).
- Davis ID, Xie W, Pezaro CJ, Donskov F, Wells C, Agarwal N, Srinivas Sandhya, Yuasa T, Beuselinck B, Wood L, Ernst DS, Kanesvaran R, Knox JJ, Pantuck AJ, Saleem S, Alva AS, Rini BI, Lee JL, Choueiri TK, Heng DYC (2016). Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy. Poster Presentation. 2016 Genitourinary Urinary Cancers Symposium, January 6-9, 2016, San Francisco, CA [Abstract]. J Clin Oncol 34, 2016 (suppl 2S; abstr 534).
- Fay AP, Kwiatkowski DJ, Gray KP, Thorner A, Rini BI, Agarwal N, Ho TH, Song J, Barrios PM, Albiges L, Mendel Van Allen E, Krajewski KM, Porta C, Pal SK, Bellmunt J, McDermott DF, Heng DYC, Signoretti S, Choueiri TK (2015). Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort. Poster Presentation. ASCO Annual Meeting May 29-June1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 4519).
- Agarwal N, Alex A, Farnham JM, Patel SB, Tantravahi SK, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA (2015). Association of single nucleotide polymorphisms (SNPs) in ESR1 and PRMT8 and reponse to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 5048).
- Li H, Choueiri TK, Welss C, Agarwal N, Donskov F, Lee J, Broom RJ, Yuasa T, Rini BI, Pal SK, Wood L, Ernst DS, Kollmannsberger CK, Vaishampayan UN, Rha SY, Bjarnason GA, Knox JJ, Saleem S, Beuselinck B, Heng DYC (2015). Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC). Poster Presentation. ASCO Annual Meeting May 29-June1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 4558).
- Palmbos PL, Feng FY, Tomlins SA, Kelly WK, Morgans AK, Taplin M, Agarwal N, Antonarakis ES, Twardowski P, Jacobson J, Davenport MS, Daignault S, Knudsen KE, Hussain M (2015). A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer. Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr TPS5074).
- Harshman LC, Werner L, Wong Y, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Recine F, Bellmunt J, Galsky MD, RISC Investigators (2015). Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 4524).
- Twardowski P, Plets M, Plimack ER, Agarwal N, Tangen CM, Vogelzang NJ, Thompson IM, Lara P (2015). SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC). Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015 (suppl; abstr 4523).
- Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Straubhar AM, Agarwal AM, Van Atta J, Grossmann KF, Samlowski WE, Redman BG, Agarwal N, Alva AS (2015). Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2). Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL [Abstract]. J Clin Oncol 33:5s, 2015(suppl; abstr 4565).
- Bailey E, Tantravahi SK, Poole A, Wells C, Batten J, Merriman J, Stenehjem D, Agarwal N (May 2015). Association of hand-foot syndrome (HFS), treatment dose reductions (TDRs), and outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL [Abstract]. J Clin Oncol.
- Patel SB, Tantravahi SK, Gill D, Poole A, Merriman J, Batten JA, Stenehjem DD, Agarwal N (February 2015). Comparative effectiveness of first-line VEGF TKI followed by second-line therapy with either a VEGF TKI or an mTOR in patients with metastatic renal cell carcinoma. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Patel SB, Agarwal N, Hsu J, Tantravahi SK, Gill D, Vuong W, Batten JA, Stenehjem DD, Pal SK (February 2015). Everolimus (EVE) versus temsirolimus (TEM) after first-line treatment with VEGF TKI in patients with metastatic renal cell carcinoma. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Cannon-Albright LA, Teerlink C, Alex A, Albright FS, Stephenson RA, Agarwal N (February 2015). A genome-wide linkage study of lethal prostate cancer predisposition gene in a set of high-risk pedigrees. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Albright FS, Agarwal N, Lowrance WT, Stephenson RA, Alex A, Cannon-Albright LA (February 2015). Risk for death from prostate cancer predicted from complete family history of lethal prostate cancer (LPC). Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Tanravahi SK, Patel SB, Ravulapati S, Batten JA, Merriman J, Stenehjem D, Agarwal N (February 2015). Long-term response in metastatic renal cell carcinoma patients receiving first-line therapy with VEGF TKIs. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Buckley TH, Patel SB, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N (February 2015). Correlation of baseline serum testosterone (T) and prostate-specific antigen (PSA) at 7 months (7 mo PSA) in patients (pts) with new hormone sensitive metastatic prostate cancer (mHSPC) treated with continous androgen deprivation therapy (cADT). Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Agarwal N, Buckley TH, Farnham JM, Patel SB, Alex A, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA (February 2015). Germ line predictors of response to androgen deprivation therapy in men with advanced prostate cancer. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Ramos J, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Sternberg CN, Alva AS, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY (February 2015). Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT). Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Eigl BJ (February 2015). Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Flaig TW, Tangen CM, Hussain M, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM (February 2015). Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL [Abstract]. J Clin Oncol.
- Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal A, Sendilnathan A, Van Atta J, Batten J, Grossmann K, Samlowski W, Stenehjem D, Agarwal N (May 2014). Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). Poster Presentation. 2014 ASCO Annual Meeting May 30–June 3, 2014, Chicago, IL [Abstract]. J Clin Oncol.
- Ko JJ, Xie W, Heng DY, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Harshman LC, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Bamias A, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK (January 2014). The international metastatic renal cell carcinoma database consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT). Oral Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 398.
- Heng DY, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Kanesvaran R, Choueiri TK (January 2014). Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Oral Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA [Abstract]. Jorunal of Clinical Oncology, 32(suppl 4), abstr 396.
- Tsao CK, Agarwal N, Apolo AB, Lee KM, Godbold JH, Oh WK, Galsky MD (January 2014). Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma. Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 18.
- Cheng HH, Nadal R, Gulati R, Azad A, Twardowski P, Vaishampayan U, Agarwal N, Heath E, Pal SK, Rehman H, Leiter A, Batten J, Montgomery RB, Galsky MD, Chi KN, Antonarakis ES, Yu EY (January 2015). The Effect of Prior Abiraterone (Abi) Use on the Efficacy of Enzalutamide (Enza) in Men with mCRPC. Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 18.
- Batten JA, Samlowski W, Parikh K, Sendilnathan A, Van Atta J, Batten JA, Sagesser D, Grossmann K, Tantravahi SK, Stenehjem DD, Agarwal N (January 2014). The association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2) Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstra 487.
- Parikh K, Stenehjem DD, Sendilnathan A, Crispin H, VanAtta J, Batten JA, Sagesser D, Grossmann K, Samlowski W, Tantravahi SK, Agarwal N (January 2014). Conditional survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD-IL2). Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 460.
- Tantravahi SK, Stenehjem DD, Agarwal A, Kollepara SL, Batten JA, Ward M, Albertson D, Wang JF, Liu T, Agarwal N (January 2014). Clinical outcomes and survival of patients (pts) with sarcomatoid metastatic renal cell carcinoma (smRCC). Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA [Abstract]. Journal of Clinical Oncology, 32(suppl 4), abstr 535.
- Diamond JR, Agarwal N, Bowles D, Lam ET, Werner T, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (May 2014). Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors. Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL Accepted [Abstract].
- Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, De Wit R, De Bono JS, Cruz F, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak P, Lee C, Tejura B, Borgstein NG, Dreicer R (May 2014). Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel. Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL Accepted [Abstract].
- Albiges L, Xie W, Lee JL, Rini B, Srinivas S, Bjarnason G, Ernst S, Wood L, Vaishamayan U, Rha SH, Agarwal N, Yuasa T, Pal SK, Koutsoukos K, Fay AP, Preston M, Cho E, Chin Heng DY, Choueiri T (May 2014). The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell cancer database consortium. Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL Accepted [Abstract].
- Galsky M, Harshman L, Crabb S, Wong YN, Yu E, Chowdhury S, Powles T, Pal SK, Moshier E, Ladoire S, Hussain S, Agarwal N, Vaishampayan U, Recine F, Berthold D, Necchi A, Theodore C, Milowsky M, Bellmunt J, Rosenberg J (May 2014). Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). Poster discussion session. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL Accepted [Abstract].
- Cheng H, Li H, Higano C, Tangen C, Agarwal N, Yan J, Vogelzang N, Hussain M, Thompson Jr I, Tewari M, Yu E (May 2014). Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer. Poster discussion session. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted [Abstract].
- Yu E, Tangen C, Higano C, Agarwal N, Pal SK, Alva AS, Heath E, Tat Lam E, Gupta S, Lilly M, Inoue Y, Chi K, Vogelzang N, Quinn D, Li H, Cheng H, Plymate S, Hussain M, Thompson Jr I (May 2014). SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. Oral Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted [Abstract].
- Agarwal N, Tangen C, Hussain M, Lara Jr P, Higano C, Vaena D, MacVicar G, Li H, Crispino T, Quinn D, Vogelzang N, Thompson Jr I (May 2014). SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) + TAK-700 with ADT + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer (HSPC) (NCT01809691). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted [Abstract].
- Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal A, Sendilnathan A, Van Atta J, Batten J, Grossmann K, Samlowski W, Stenehjem D, Agarwal N (May 2014). Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted [Abstract].
- Agarwal N, Parikh K, Tantravahi SK, Van Atta J, Batten J, Sageser D, Samlowski W, Grossmann K, Wang J, Stenehjem D (May 2014). Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL Accepted [Abstract]. Journal of Clinical Oncology.
- Stenehjem D, Parikh K, Batten J, Van Atta J, Crispin H, Sageser D, Grossmann K, Wang J, Tantravahi SK, Samlowski W, Agarwal N (2014). Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2) [Abstract]. Journal Of Clinical Oncology.
- Sonpavde G, Pond GR, Agarwal N, Choueiri TK, Qu AQ, Fougeray R, Salhi Y, Vaughn DJ, James ND, Niegisch G, Albers P, Galsky MD, Wong YN, Stadler WM, ODonnell PH, Vogelzang NH, Sridhar SS, Ko YJ, Sternberg CN, Bellmunt J (2013). Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC). Poster Discussion. American Society of Clinical Oncology (ASCO) Annual Meeting Chicago IL. May 31-Jun 4, 2013 [Abstract].
- Chittoria N, Zhu H, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox J, Bjarnason BA, MacKenzie MK, Wood L, Vaishamayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, North SA, Rini BI, Yick D, Heng C (2013). Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium. Poster Presentation. May 31-Jun 4, 2013.ASCO annual meeting Washington D.C [Abstract].
- Agarwal N, Wade M, Batten J, Davidson C, Sun SL, Sharma S (2013). Phase I Study of Histone Deacetylase Inhibitor Belinostat in Combination with Warfarin in Patients with Solid Tumors or Hematological Malignancies. Accepted for Poster Presentation (Abstract: 1187): April, 8, 2013 AACR annual meeting. Washington, DC [Abstract].
- Heng DYC, ChoueiriTK, Lee JL, Harshman LC, Bjarnason G, Knox JJ, MacKenzie MJ, Vaishampayan UL, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North, S, A, Rini BI, Wood L (2012). A multicentered population based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials. (Abstract 353). Oral Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol 30, 2012.
- Agarwal N, Boucher KM, Maughan B, Hussain SA, Kaufman DS, LorussoV, Moore MJ, Galsky MD, Sonpavde G (2012). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. (Abstract #308). Poster Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol, 30(Suppl 5), abstr 308.
- Kinney A, Birmingham W, Kohlmann W, Agarwal N (August 2012). Patients and providers cognitions regarding genomic risk assessments for prostate cancer susceptibility and cancer prevention. Oral Presentation Aug 2012 Prague, Czech Republic [Abstract]. European Health Psychology Society.
- Munster P, van der Noll R, Voest E, Specht J, Werner TL, Dees EC, Tan AR, Daud A, Schellens J, Lolkema MP, Griffin M, Agarwal N, Falchook GS, Kleha JF, Durante M, Smith DA, Adams L, Greshock J, Morris SR, Kurzrock R (9/2012). PI3K kinase inhibitor GSK2126458 (GSK458): Clinical activity in select patient (pt) populations defined by predictive markers (Study P3K112826). Oral Presentation European Society of Medical Oncology, September 2012, Vienna, Austria [Abstract]. European Society of Medical Oncology.
- Kanth P, Stayner J, Grossman K, Agarwal N, Peterson K, Boynton K, Fang J, Valentine J, Bronner M, Burt R, Jewel Samadder N (2012). Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody (Ipilimumab) Associated Enterocolitis. Poster Presentation (P861)ACG), 77th Annual Meeting, October 19 - 24, 2012, Las Vegas, Nevada [Abstract]. American College of Gasteroenterology.
- Choueiri TK, Xie WL, Harshman LC, Bjarnason G, Knox JJ, MacKenzie MJ, Wood L, Vaishampayan UL, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, Heng DYC (2012). Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) targeted therapy (TT): Results from the international mRCC database consortium. Poster Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol, 30(suppl 5), abstr 358.
- Heng DYC, Lee JL, Harshman LC, Bjarnason G, Razak AR, MacKenzie MJ, Wood L, Vaishampayan UI, Tan MH, Ran SY, Donskov F, Agarwal N, Kollmannsberger CK, North S, Rini BI, Choueiri TK, International mRCC Database Consortium (2012). A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). Poster Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol 30, 2012 (suppl 5; abstr 387).
- Heng DYC, Xie WL, Choueiri TK, Lee J, Harshman LC, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Vaishampayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, and Choueiri TK (2012). An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials. Oral Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA [Abstract]. J Clin Oncol 30, 2012 (suppl 5; abstr 353).
- Cannon Albright LA, Teerlink C, Agarwal N, Stephenson R (2011). Evidence for a strong genetic contribution to lethal prostate cancer (Abstract-1205W). Poster Presentation International Congress of Human Genetics/ American Society of Human Genetics. October 11-15, 2011, Montreal, Quebec, Canada [Abstract].
- Lam ET, Wong MKK, Agarwal N, Redman BG, Logan T, Flaig TW, Monk III JP, Jarkowski A, Sendilnathan A, Bolden M, Kuzel T, Olencki T (2011). Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma [Abstract]. J Clin Oncol, 29(suppl), e15079.
- Agarwal N, Sahu M, Abhyankar DJ, Werner TL, Benjamin B, Srinivas R, Sharma S (2011). A drug-drug interaction study of everolimus (a mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF and EphB4 receptors, in patients with advanced urologic tumors. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011. [suppl; abstr e15077] [Abstract]. J Clin Oncol, 29(suppl), e15077.
- Hess D, Hagner N, Clive S, Gelderblom H, Rossmann E, Agarwal N, Grazia Porro M, Hengelage T, St-Pierre A, Gazi L, Li J, Woo MM, Sharma S (Nov 2011). Effects of Hepatic Funtion on the Pharmacokinetics and Safety of Panobinostate in Patients with Advanced Cancer: A Phase I Study. (ASH Annual Meeting Abstracts) [Abstract]. Blood, 118, 5007.
- Sharma S, Voest E, Hagner N, Witteveen PO, Lolkema M, Agarwal N, Valera S, Li J, Mires D, Porro MG, Woo MM, and Hess D (Nov 2011). Effects of Renal Function on the Pharmacokinetics of Panobinostate in Patients with Advanced Cancer: A Phase I Study [Abstract]. Blood, 118, 5001.
- Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason GA, Wood L, Vaishampayan UL, MacKenzie MJ, Knox JJ, Agarwal N, Kollmannsberger CK, Tan MH, Rha SY, Donskov F, North S, Choueiri TK, Heng DYC (2011). The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (pts). Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011 [Abstract]. J Clin Oncol 29:2011 (suppl; abstr 5563.
- Grossmann KF, Blankenship MB, Akerley W, Terrazas MC, Kosak KM, Boucher KM, Buys SS, Jones K, Werner TL, Agarwal N, Weis J, Sharma S, Ward JH, Shami PJ (2011). A phase I clinical study investigating disulfiram and copper gluconate in patients with advanced treatment-refractory solid tumors involving the liver [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; Abstract 1308 AACR. 2011 Apr 2-6; Orlando, Florida (FL): 2011 [Abstract].
- Fury MG, Sherman EJ, Lisa DM, Agarwal N, Algazy KM, Brockstein B, Langer CJ, Lim D, Mehra R, Rajan SK, Jafri N, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng KK, Xiao H, Haque S, Pfister DG (05/23/2011). A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June, 2011 [Abstract]. J Clin Oncol, 29(Suppl), abstr 5563.
- Alva AS, Agarwal N, Siefker-Radtke AO, Roth BJ, Smith DC, Daignault S, Srinivas S, Bradley DA, Hussain M (2010). Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab. Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 4-8, 2010. [J Clin Oncol 28:7s, 2010 (suppl; abstr TPS239)] [Abstract]. J Clin Oncol 28:7s, 2010 (suppl; abstr TPS239).
- Agarwal N, Swierczek S, Nussenzveig RH, Samuelson S, Parker CJ, Prchal JT (2008). Validation of a novel clonality assay in patients with clonal hematologic disorders [Abstract]. Blood 2008; 112: Abstract 3718.
- Agarwal N, Swierczek S, Naidoo K, Prchal JT, Coetzer TL (2007). A novel Mutation of the aSpectrin Gene in a Family of Northern European Descent is Associated with Three Different Phenotypes [Abstract]. Blood. 2007; 110 (11): abstract 1717.
- Agarwal, N, Swierczek S, Rothstein G, Nussenzveig R, Prchal J (2007). Is Hematopoiesis Clonal in Healthy Elderly Females? [Abstract]. Blood, 2007; 110 (11): abstract 2243, 110(11), abstract 2243.
- Agarwal AM, Agarwal N, Tryka AF, Ward JH, Lim MS (2007). Blastic Transformation of Follicular lymphoma [Abstract]. Archives of Pathology and Laboratory Medicine (supplement), September 2007.
- Spahr JE, Agarwal N, Rodgers GM (2007). Treatment of Immune-Mediated Thrombocytopenia Purpura with Concurrent IVIg and Platelet Transfusion: A Retrospective Review of 40 Patients [Abstract]. Blood "Supplement", 108(11), A1598.
- Wada D, Agarwal N, Florell SR, Lim M (2006). Recurrent Squamous cell carcinoma and fallicular lymphoma arising in the scalp two years after treatment for lymphoma [Abstract]. Archives of Pathology and Laboratory Medicine, 130, 1362-1403 (P14).
- Agarwal N, Mojica-Henshaw MP, Kutlar F, Gaikwad A, Ou CN, Kutlar A, Prchal JT (2006). Novel Mechanism of β0 Thalassemia: Missense Mutation of the Last Nucleotide of β Globin Exon 1 (G->C) Leads to Undetectable Transcript and Mutant Peptide [Abstract]. Blood (supplement), 2006; 108: A1598.
Video/Film/CD/Web/Podcast
- Agarwal N (2016). Newly Diagnosed Metastatic Prostate Cancer Patient [Web]. Available: http://goo.gl/x4aGWO.
- Agarwal N (2016). Vaccine Therapy in Metastatic Renal Cell Carcinoma: Past, Present, and Future. ASCO Post [Web]. Available: http://goo.gl/CqKjqd.
- Agarwal N (2016). Prognostication Based on Site of Metastatic Disease in Castration Refractory Prostate Cancer: Implications for Patient Care and Clinical Trial Design, Journal of Clinical Oncology [Podcast]. Available: https://goo.gl/YE04QE.
- Gupta S, Agarwal N (2016). Cancer Immunotherapy with Interleukin-2-Current Status and Future Developments [Web]. Immunotherapy. Available: https://goo.gl/pNFqvI.
- Agarwal N (2014). Perspective opinion on “Gleason score associated with time to development of neuroendocrine prostate cancer [Web]. Available: https://goo.gl/eKj1Q1.
- Wada D, Agarwal N, Lim M (2005). Case of the Quarter: Society of Hematopathology [Web]. Society for Hematopathology. Available: http://www.sh-eahp.org/.
- Hussain I, Agarwal N (2003). DRESS syndrome associated with cephalosporin therapy [Web]. E-Letter in British Medical Journal. Available: https://goo.gl/NIq711.
Poster
- Stukalin I, Wells C, Fraccon AP, Pasini F, Porta C, Moreira RB, Srinivas S, Bowman IA, Brugarolas J, Lee JL, Donskov F, Beuselinck B, Bamias A, Rini BI, Sim HW, Agarwal N, Rha SY, Kanesvaran R, Choueriri TK, Heng DYC (2017). Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Sonpavde G, Nagy RJ, Sartor AO, Pond GR, Gourdin TS, Nandagopal L, Ledet EM, Agarwal N, Carroll E, Naik G, Wang J, Bilen MA, Grivas P, Lanman RB, Talasaz A, Lilly MB (2017). Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy. Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Palmbos PL, Tomlins SA, Agarwal N, Twardowski P, Morgans AK, Kelly WK, Arora V, Antonarakis ES, Siddiqui J, Daignault S, Knudsen KE, Feng FYC, Hussain M (2017). Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC). Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Gill DM, Stenehjem DD, Cheng HH, Kessler ER, Hahn AW, Gupta S, Alex A, Patel SB, Chittoria N, Twardowski P, Vaishampayan UN, Agarwal N (2017). Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC). Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Gupta S, Albertson DJ, Gaston D, Heilbrun ME, Agarwal N, Liu T, Miller VA, Ross JS, Millis SZ, Ali SM (2017). Comprehensive genomic sequencing of urothelial tumors to identify rare driver genomic alterations in SMARCB1 in a subset of patients. Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Gupta S, Albertson DJ, Parnell T, Dalley B, Shea JO, Weston A, Butterfield A, Pappas LM, Schiffman JD, Sharma S, Agarwal N (2017). Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC). Poster session presented at Genitourinary Cancers Symposium, Orlando.
- Gill DM, Agarwal N, Hahn AW, Johnson E, Poole A, Carroll E, Boucher KM, Salama ME, Agarwal AM (2017). Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC). Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Gill DM, Gaston D, Hahn AW, Bailey EB, Buckley TH, Johnson E, Batten JA, Alex A, Boucher KM, Stenehjem DD, Agarwal N (2017). Efficacy of eplerenone (Epe) in the management of mineralocorticoid excess (MCE) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (AA) without prednisone (P). Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Carroll E, Gill DM, Poole A, Hahn AW, Bailey EB, Streeter J, Batten JA, Gupta S, Agarwal N, Maughan BL (2017). Genomic diversity between primary tumor tissue and tumor circulating cell-free DNA (cfDNA) in patients (pts) with metastatic prostate cancer. Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Hahn AW, Gill DM, Poole A, Farnham JM, Cannon-Albright LA, Agarwal N (2017). Independent validation of effect of HSD3B1 genotype on response to androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer (HSPC). Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Poole A, Gill DM, Hahn AW, Johnson E, Carroll E, Batten JA, Gupta S, Boucher KM, Maughan BL, Agarwal N (2017). Incidence and characterization of antiandrogen withdrawal syndrome (AAWS) after enzalutamide (ENZA) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Vogelzang NJ, Pal SK, Ghate S, Li N, Swallow E, Peeples M, Zichlin M, Meiselback M, Perez JR, Agarwal N (2017). Real-world economic outcomes among patients (pts) who initiated sunitinib or pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data. Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Hammers HJ, Drake CG, Zakharia Y, Kennedy EP, Vahanian NN, Link CJ, Agarwal N (2017). A phase 1 study of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients with metastatic renal cell cancer. Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Hahn, AW, Gill, DM, Streeter J, Bailey EB, Carroll E, Aryal L, Batten JA, Gupta S, Agarwal N, Maughan BL (2017). Intra-individual genomic diversity between circulating tumor cell-free DNA (cfDNA) and tumor tissue testing in metastatic renal cell carcinoma (mRCC). Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Twardowski P, Wong J, Pal SK, Frankel PH, Franklin K, Junqueira M, Prajapati MR, Harwood D, Agarwal N (2017). Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-t alone in patients with metastatic castrate resistant prostate cancer. Poster session presented at 2017 Genitourinary Cancers Symposium, Orlando.
- Vogelzang NJ, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N (2017). Real-world outcomes among patients who initiated pazopanib or Sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data. Poster session presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Boston.
- Tagawa S, Chatta GS, Pal SK, Goel S, Mazhari R, Heaton C, Benaim E, Agarwal N (2016). Phase Ib/II Study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma - Phase Ib results. Poster session presented at AACR Annual Meeting, New Orleans, LA.
- Schwartz G, Adkins D, Heist R, Werner T, Abbott M, Barber S, Slusarz K, Agarwal N, Neuteboom S, Faltaos D, Chen I, Christensen J, Chao R, Bauer T (2015). A first-in-human phase 1/1b study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors. Poster session presented at 18th ECCO-40th ESMO European Cancer Congress, Vienna, Austria.
- Carducci M, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang NJ, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bgemann M, Hutson T, Milecki P, Nederman T, Sternberg C (2015). A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC). Poster session presented at 18th ECCO-40th ESMO European Cancer Congress, Vienna, Austria.
- Pal S, Vuong W, Zhang W, Deng J, Liu X, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin R, Agarwal N, Jones J (2015). Clinical and translational assessment of VEGFR1 as a mediator of the pre-metastatic niche: Neoadjuvant axitinib in high-risk localized prostate cancer. Poster session presented at 18th ECCO-40th ESMO European Cancer Congress, Vienna, Austria.
- Harshman L, Werner L, Wong YN, Yu E, Alva E, Crabb S, Powles T, Rosenberg J, Baniel J, Vaishampayan U, Berthold D, Ladoire S, Hussain S, Milowsky M, Agarwal N, Necchi A, Pal S, Recine F, Bellmunt J, Galsky M (2015). Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). Poster session presented at 18th ECCO-40th ESMO European Cancer Congress, Vienna, Austria.
- Agarwal N, Buckley TH, Farnham JM, Patel SB, Agarwal AM, Tantravahi SK, Teerlink C, Albright FS, Stephenson RA, Alex A, Cannon-Albright LA (2015). Association of single nucleotide polymorphisms (SNPs) in STS and SULT2B1 and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive prostate cancer (aHSPC). Poster session presented at AACR Precision Medicine: Integrating Clinical Genomics and Cancer Therapy, Salt Lake City, UT.
- Cannon-Albright LA, Teerlink CC, Stephenson RA, Agarwal N (April 2015). Significant evidence for linkage for lethal prostate cancer on chromosome arm 4q in Utah high-risk pedigrees. Poster session presented at 2015 American Association for Cancer Research (AACR) Annual Meeting, Philadelphia, PA.
- Albright FS, Agarwal N, Lowrance WT, Stephenson RA, Cannon-Albright LA (2015). Risk for death from prostate cancer predicted from complete family history of lethal prostate cancer. Poster session presented at 2015 American Association for Cancer Research (AACR) Annual Meeting, Philadelphia, PA.
- Penson D, Armstrong A, Concepcion R, Agarwal N, Wang F, Wu K, Amelsberg A, Phung D, Higano C (May 2015). A Multicenter Phase 2 Study of Enzalutamide (ENZA) versus Bicalutamide (BIC) in Men with Nonmetastatic (M0) or Metastatic (M1) Castration-Resistant Prostate Cancer (CRPC): the STRIVE Trial. Poster session presented at 2015 American Urological Association’s (AUA) Annual Meeting, New Orleans, LA.
- Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM (June 2015). MDFDG- and FLT-PET for early measurement of response to 37.5 mg per day of sunitinib in metastatic renal cell carcinoma. Poster session presented at Society of Nuclear Medicine and Molecular Imaging, Baltimore, MD.
- Diamond JR, Agarwal N, Bowles D, Lam ET, Werner T, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S (04/10/2014). Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors. Poster Presentation Accepted for ASCO. Poster session presented at ASCO Annual Meeting May 30 - June 3, 2014, Chicago, IL.
- Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, De Wit R, De Bono JS, Cruz F, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak P, Lee C, Tejura B, Borgstein NG, Dreicer R (May 2014). Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel. Accepted for Poster Presentation at ASCO. Poster session presented at Annual ASCO Meeting May 30 - June 3, 2014, Chicago, IL.
- Galsky M, Harshman L, Crabb S, Wong YN, Yu E, Chowdhury S, Powles T, Pal SK, Moshier E, Ladoire S, Hussain S, Agarwal N, Vaishampayan U, Recine F, Berthold D, Necchi A, Theodore C, Milowsky M, Bellmunt J, Rosenberg J (May 2014). Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). Accepted for Poster discussion session at ASCO. Poster session presented at ASCO Annual Meeting May 30 - June 3, 2014, Chicao, IL.
- Cheng H, Li H, Higano C, Tangen C, Agarwal N, Yan J, Vogelzang N, Hussain M, Thompson Jr I, Tewari M, Yu E (May 2014). Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer. Accepted for poster discussion session at ASCO. Poster session presented at ASCO Annual Meeting May 30 - June 3, 2014, Chicago, IL.
- Yu E, Tangen C, Higano C, Agarwal N, Pal SK, Alva AS, Heath E, Tat Lam E, Gupta S, Lilly M, Inoue Y, Chi K, Vogelzang N, Quinn D, Li H, Cheng H, Plymate S, Hussain M, Thompson Jr I (May 2014). SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. Oral Presentation accepted at ASCO. Poster session presented at ASCO Annual Meeting May 30 - June 3, 2014, Chicago, IL.
- Agarwal N, Tangen C, Hussain M, Lara Jr P, Higano C, Vaena D, MacVicar G, Li H, Crispino T, Quinn D, Vogelzang N, Thompson Jr I (May 2014). SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) + TAK-700 with ADT + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer (HSPC) (NCT01809691). Poster session presented at ASCO Annual Meeting May 30 - June 3, 2014, Chicago, IL.
- Bailey E, Tantravahi SK, Poole A, Wells C, Batten J, Merriman J, Stenehjem D, Agarwal N (May 2014). Association of hand-foot syndrome (HFS), treatment dose reductions (TDRs), and outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). Accepted for Poster Presentation ASCO May 30-June 3, 2014. Poster session presented at ASCO Annual Meeting May 30 - June 3, 2014, Chicago, IL.
- Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal A, Sendilnathan A, Van Atta J, Batten J, Grossmann K, Samlowski W, Stenehjem D, Agarwal N (2014). Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). Accepted Poster Presentation for ASCO Meeting May 30-June 3, 2014. Poster session presented at 2014 ASCO Annual Meeting May 30–June 3, 2014, Chicago, IL.
- Reid J, Graves KK, Haslem DS, Agarwal N (2009). Bleeding due to Factor XIII deficiency is associated with normal screening coagulation tests. Poster session presented at American College of Physicians (ACP) Annual Meeting, April April 23-25, 2009., Philadelphia, PA..
- Graves KK, Reid J, Nord John, Haslem DS, Agarwal N (2009). EDTA-dependent pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Poster session presented at American College of Physicians (ACP) Annual Meeting, Philadelphia, PA, April 23-25, 2009., Philadelphia, PA.
- Nussenzveig R, Swierczek S, Agarwal N, Prchal J (2008). Hematopoiesis is Not Clonal in Healthy Elderly Females? [Abstract published in: Stem cells, Cancer and Aging 2008; 77: abstract 250]. Poster session presented at Stem Cells, Cancer and Aging. Keystone Symposia. 29 September - 3 October 2008., Singapore..
- Agarwal AM, Agarwal N, Glenn M, Lim H (2008). Spontaneous splenic rupture complicating primary treatment refractory Burkitt lymphoma. [Published: Archives of Pathology and Laboratory Medicine, 2008; 132: 1454 -1527]. Poster session presented at American Pathologists (CAP) annual meeting, September 2008, San Diego, CA.
- Agarwal N, Swierczek S, Lorenzo FR, Naidoo K, Agarwal AM, Nussenzveig RH, Whisenant J, Coetzer TL, Prchal JT (2008). Novel exon 2 alpha spectrin mutation in a Caucasian family with pyropoikilocytosis, elliptocytosis, and normal morphology: three phenotypes due to decreased spectrin mRNA and intragenic crossover [Abstract published in journal: Blood 2008; 112: Abstract 3840]. Poster session presented at American Society of Hematology (ASH) Annual Meeting, San Francisco, CA.
- Agarwal N, Ippolito L, Mitros FA, Goeken J, Schimdt WN, Voigt MD, LaBrecque DR (2003). Clinical Significance of atypical p-ANCA and ANA in autoimmune hepatitis.[Abstract published: Hepatology (supplement), October 2002]. Poster session presented at American College of Physicians Annual Meeting, April, 2003., San Diego, CA.
- Agarwal N, Kirby P, White ML, Jogerst GJ, Grabowski TJ (2003). A Rapidly Progressive Case of Sporadic Progressive Sub cortical Gliosis (PSG). Poster session presented at Annual Dementia Congress, Washington D.C..
Global Impact
Education History
| Professional Medical | All India Institute of Medical Sciences Medicine M.D. |
| Professional Medical | Assam Medical College Medicine M.B.B.S. |